The pharmaceutical company Boehringer Ingelheim ANZ (BI) has notified us of the discontinuation of Metalyse (tenecteplase) 40 mg powder for injection from early September 2024. BI anticipate that stock will be depleted in Australia by the end of January 2025. The decision to discontinue Metalyse 40 mg has been made by the company on the basis of low and diminishing demand for this product in Australia.
Metalyse 50 mg will continue to be available, and there is no change to anticipated supply volumes for 2024. Current allocation arrangements with states and territories will continue. BI have informed us that this discontinuation will allow production of the 50 mg product to be streamlined. Supply of Metalyse 50 mg is anticipated to return to normal in early 2025.
More information about the shortage of Metalyse (tenecteplase) products is available from the Metalyse (tenecteplase) shortage collection.